November 14, 2025
FOCUS on Drug Repurposing. Moxidectin is an anthelmintic drug approved by the FDA in 2018 for onchocerciasis (river-blindness). It is a derivative of milbemycin, a structurally […]
November 14, 2025
FOCUS on New Drug Approvals. The FDA has approved Boehringer Ingelheim’s Nerandomilast (Jascayd, BI-101555) for patients with idiopathic pulmonary fibrosis (IPF) a rare, serious, and progressive […]
November 11, 2025
FOCUS on MS Drug Development. Roche announced this week that the first of two pivotal phase III studies (FENhance 1 and 2) in patients with relapsing […]
November 6, 2025
FOCUS on New Drug Approvals. The FDA just announced approval of Revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children with relapsed […]
November 5, 2025
FOCUS on Drug Failures. The FDA rejected Biohaven’s glutamate modulator Troriluzole for treatment of spinocerebellar ataxia, a rare and life-threatening neurodegenerative disease with no treatment options. […]
October 29, 2025
FOCUS on SIRT6. Sirtuin 6 (SIRT6) is an NAD-dependent histone deacetylase shown to function as a tumor suppressor in several cancer types. However, the therapeutic potential […]
October 21, 2025
FOCUS on CRISPR. October 20 is World CRISPR day, celebrating this powerful gene-editing technology. FOCUS Biomolecules offers a large variety of small molecules used to enhance […]
October 8, 2025
FOCUS on boosting tumor immunogenicity. In a paper just out in PNAS, researchers at UMass Chan Medical School report that PPT1 (Palmitoyl Protein Thioesterase 1) is […]
September 18, 2025
FOCUS on Neuroblastoma. In a paper just out in Nature Communications, Singh et al. report: “To better understand the cellular plasticity of neuroblastoma in chemoresistance, we […]